Lxekizumab in the management of on selected outpatients with moderate to severe psoriasis - New data and personal clinical experience
Spring Dermatology & Skin Care Expo Conference
May 14-15, 2018 | Montreal, Canada
Scientific Tracks Abstracts : Dermatol Res Skin Care
Based on broad personal experience in dermatology and especially in the management of patients with moderate to severe psoriasis (track of >20 years of serving both inpatients and outpatients) new data from clinical studies with ixekizumab is presented. This contains new data on long-term-efficacy of ixekizumab, effectiveness in special localizations (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis) as well as safety data and experiences on patients switched to ixekizumab from other biologics. Personal clinical experience from my specialized outpatient dermatology center (>300 nonselected outpatients with moderate to severe psoriasis, >250 patients on biological therapies, >50 patients on ixekizumab) is discussed. Focusing on a relevant number of patients switched from secukinumab to ixekizumab due to first or secondary loss of efficacy significant differences between both IL-17A-inhibitors mainly in terms of efficacy and speed of therapeutic response are shown. Finally, the correlation between PASI-90-/PASI-100 response and significant changes in DLQI is highlighted.
Norbert Behnke is currently working in private practice as a Psoriasis-Specialist in Germany. She is a reviewer of multiple journals with editorial positions in others. Her expertise includes an interest in the Dermatology and psoriasis of disease including acne, wound healing and psoriasis.